Please Wait
Applying Filters...
menu
    • menu
    Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

    Stock Recap
    #PipelineProspector

    Menu

    Dalbavancin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 128,762Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/03/2025 BrightGene Bio-Medical Technology Co.,Ltd
    China
    		 BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD 37185 DALBAVANCIN PRECURSOR A40926 (CBR48) 2022-09-14 Active II N/A
    28/03/2025 BrightGene Bio-Medical Technology Co.,Ltd
    China
    		 BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD 36025 DALBAVANCIN PRECURSOR A40926 2021-08-25 Active II N/A